NCT04275960View on ClinicalTrials.gov

Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

October 1, 2020

Study Completion Date

November 30, 2020

Conditions

Solid Tumors Harboring NTRK Fusion

Interventions

DRUG

Selitrectinib (BAY2731954)

Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.

Trial Locations (1)

68167

CRS Clinical-Research-Services Mannheim GmbH, Mannheim